<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440660</url>
  </required_header>
  <id_info>
    <org_study_id>4C-2011-01</org_study_id>
    <nct_id>NCT01440660</nct_id>
  </id_info>
  <brief_title>Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER)</brief_title>
  <official_title>Phenotypes of Nonproliferative Diabetic Retinopathy in Diabetes Type 2 Patients Identified by Optical Coherence Tomography, Colour Fundus Photography, Fluorescein Leakage and Multifocal Electrophysiology (DIAMARKER Project: Genetic Susceptibility for Multi-systemic Complications in Diabetes Type-2: New Biomarkers for Diagnostic and Therapeutic Monitoring).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association for Innovation and Biomedical Research on Light and Image</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Coimbra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Association for Innovation and Biomedical Research on Light and Image</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterise phenotypes of Non Proliferative Diabetic Retinopathy (NPDR) progression using
      multimodal testing/imaging procedures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Multimodal testing/imaging procedures - Ophthalmological Imaging</measure>
    <time_frame>24 months</time_frame>
    <description>Retinal thickness measured with OCT;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multimodal testing/imaging procedures - Ophthalmological Imaging</measure>
    <time_frame>24 months</time_frame>
    <description>MA turnover computed based on CFP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multimodal testing/imaging procedures - Ophthalmological Imaging</measure>
    <time_frame>12 months</time_frame>
    <description>Macular area with increased retinal fluorescein leakage based on RLA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multimodal testing/imaging procedures - Ophthalmological Imaging</measure>
    <time_frame>12 months</time_frame>
    <description>Implicit time local and ring amplitudes measured with mfERG.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multimodal testing/imaging procedures - Psychophysical Testing</measure>
    <time_frame>12 months</time_frame>
    <description>Psychophysical tests for speed discrimination, achromatic contrast, and chromatic contrast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multimodal testing/imaging procedures - Barin Imaging</measure>
    <time_frame>12 months</time_frame>
    <description>Perfusion change measured with ASL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multimodal testing/imaging procedures - Ophthalmological Imaging</measure>
    <time_frame>12 months</time_frame>
    <description>Blood-Brain Barrier alterations assessed contrast agent with Dynamic MR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multimodal testing/imaging procedures - Brain Imaging</measure>
    <time_frame>12 months</time_frame>
    <description>Metabolite concentrations assessed with MR Spectroscopy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multimodal testing/ imaging modalities (raw data)</measure>
    <time_frame>24 months</time_frame>
    <description>Raw data obtained from the different modalities (OCT,MA turnover, RLA,mfERG, psychophysical tests, ASL, Dynamic MR and MR Spectroscopy).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Type-2 Diabetes</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Leaking Phenotype</arm_group_label>
    <description>Retinal thickness (RT) increase (increase in RT above normal range as measured by OCT, considering the macular thickness normative data) in the central subfield, the inner ring and/or the outer ring.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ischemic Phenotype</arm_group_label>
    <description>Neovascular disease activity as shown by microaneurysms (MA) turnover (MA formation rate &gt;= 2, i.e. number of new MA per year) computed from CFP using the RetmarkerDR software.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of 20 patients, male and female over 18 years-old, with
        type-2 diabetes mellitus and NPDR with signs of DR progression (RT increase and/or MA
        turnover) (according to the inclusion/exclusion criteria).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age over 18 years-old.

          2. Diabetes mellitus type 2 according to 1985 WHO criteria.

          3. Non-proliferative diabetic retinopathy (ETDRS level &lt;= 35)

          4. Signs of NPDR progression based on existing clinical information:

               1. Retinal thickness (RT) increase (increase in RT above normal range as measured by
                  OCT, considering the macular thickness normative data) in the central subfield,
                  the inner ring and/or the outer ring (leaking phenotype); OR

               2. Neovascular disease activity as shown by microaneurysms (MA) turnover (MA
                  formation rate &gt;= 2, i.e. number of new MA per year) computed from CFP using the
                  RetmarkerDR software (ischemic phenotype).

          5. Informed consent.

        Exclusion Criteria:

          1. Cataract or other eye disease that may interfere with fundus examinations

          2. Any eye surgery or treatment within a period of 6-months.

          3. Pregnant or nursing (lactating) women.

          4. Patients with chronic or severe kidney disease (glomerular filtration rate, GFR &lt; 30
             mL/min/1.73m2).

          5. Patients with acute kidney injury.

          6. Patients with known allergic or hypersensitivity reactions to gadolinium, versetamide
             or any of the inert ingredients.

          7. Patients around the time of liver transplantation..

          8. Patients with implants containing metals.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Cunha-Vaz, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Association for Innovation and Biomedical Research on Light and Image</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Castelo-Branco, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>FMUC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luísa Ribeiro, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIBILI - CEC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AIBILI - Clinical Trials Centre (CEC)</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-548</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2011</study_first_submitted>
  <study_first_submitted_qc>September 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2011</study_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

